Generic and therapeutic statin switches and disruptions in therapy

Current Medical Research and Opinion

Volumn 25, Issue 5, 2009, Pages 1247-1260

  Chapman, Richard H ^a,f   Benner, Joshua S ^a,b   Girase, Prafulla ^a   Benigno, Michael ^c   Axelsen, Kirsten ^c   Liu, Larry Z ^c,d   Nichol, Michael B ^e  

^a IQVIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PFIZER INC   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f IMS Consulting   (United States)

Author keywords

Adherence; Generic substitution; Quality of care; Statins

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DESIGNER DRUG; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID; POTASSIUM SPARING DIURETIC AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; WARFARIN;

ADULT; AGED; ARTICLE; BIOEQUIVALENCE; DRUG MEGADOSE; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENERIC DRUG SUBSTITUTION; HEALTH INSURANCE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG UTILIZATION; DRUGS, GENERIC; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POLYPHARMACY; RETROSPECTIVE STUDIES; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 67649390894     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902876271     Document Type: Article

References (31)

1. Guidelines for therapeutic interchange. American College of Clinical Pharmacy. Pharmacotherapy 1993;13:252-256 (Pubitemid 23162480)
2. Antman EM, Ferguson JJ. Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents? Circulation 2003;108:2604-2607
3. Kereiakes DJ, Willerson JT. Therapeutic substitution: guilty until proven innocent. Circulation 2003;108:2611-2612 (Pubitemid 37466799)
4. Verispan Vector One National Data. Monthly switch rates in the Lipid Lowering Market Jan-05 through May-07. Custom analysis performed in July 2008 (data on file)
5. Boston News WCVB investigative report, August 1, 2007. Available at: http://www.thebostonchannel.com/news/13800173/detail.html
6. Solomont EB. Insurers pay doctors to push generic drugs. New York Sun. July 16, 2008. Available at: http://www.nysun.com/business/insurers-pay-doctors- to-push-generic-drugs/81992/
7. Taylor AJ, Grace K, Swiecki J, et al. Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. Pharmacotherapy 2001;21:1130-1139 (Pubitemid 32807874)
8. Schneeweiss S, Maclure M, Dormuth CR, et al. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther 2006;79:379-388
9. Food and Drug Administration Office of Generic Drugs. U.S. Food and Drug Administration website: what are generic drugs? Available at: http://www.fda.gov/cder/ogd/index.htm Introduction [Last accessed 9 June 2008]
10. Mignini F, Tomassoni D, Streccioni V, et al. Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers. Clin Exp Hypertens 2008;30:95-108 (Pubitemid 351302226)
11. Assawawitoontip S, Wiwanitkit V. A randomized crossover study to evaluate LDL-cholesterol lowering effect of a generic product of simvastatin (Unison Company) compared to simvastatin (Zocor) in hypercholesterolemic subjects. J Med Assoc Thai 2002;85(Suppl. 1):S118-24
12. Fox KM, Gandhi SK, Ohsfeldt RL, et al. Comparison of lowdensity lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care 2007;13(Suppl. 10):S270-5
13. Krasuski RA, Doeppenschmidt D, Henry JS, et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. Mayo Clin Proc 2005;80:1163-1168 (Pubitemid 41233353)
14. Raal FJ. A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin. Cardiovasc J S Afr 2004;15:118-123 (Pubitemid 39056139)
15. Rindone JP, Arriola G. Conversion from fluvastatin to simvastatin therapy at a dose ratio of 8 to 1: effect on serum lipid levels and cost. Clin Ther 1998;20:340-346 (Pubitemid 28241753)
16. Rindone JP, Arriola G, Hiller D, et al. Changes in serum lipids when fluvastatin is substituted for lovastatin in the same doses. Am J Cardiol 1997;80:348-349 (Pubitemid 27330157)
17. Usher-Smith J, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-484 (Pubitemid 351197428)
18. Usher-Smith JA, Ramsbottom T, Pearmain H, et al. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract 2007;61:15-23 (Pubitemid 46269345)
19. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004;147:705-713 (Pubitemid 38900464)
20. Phillips BRC, Rudolph AE, Morant S, et al. Switching statins: the impact on patient outcomes. Br J Cardiol 2007;14:280-285 (Pubitemid 350226458)
21. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-467 (Pubitemid 34787477)
22. Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics 2006;24(Suppl. 3):65-78
23. Minhas R, Bogle RG, Patel KC, et al. Pharmacopolitics, statin switching and therapeutic substitution: much ado about something. Int J Clin Pract 2008;62:354-355 (Pubitemid 351197431)
24. Atar D, Carmena R, Clemmensen P, et al. Clinical review: impact of statin substitution policies on patient outcomes. Ann Med 2009;4:1-15
25. Joyce AT, Harrison DJ, Loebel AD, et al. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care 2005;11:S254-61 (Pubitemid 41361627)
26. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154-159 (Pubitemid 46269874)
27. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-213 (Pubitemid 30044262)
28. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16:366-85; discussion 365 (Pubitemid 24321670)
29. Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States: Looking beyond the turning point. Health Affairs 2008;28:w151-60
30. Druss BG, Marcus SC, Olfson M, et al. Listening to generic Prozac: winners, losers, and sideliners. Health Affairs 2004;23:210-216 (Pubitemid 39303506)
31. Speedy switch to generic Prozac. Medical Marketing & Media. Sept. 2001. Available at: http://findarticles.com/p/articles/mi-qa5351/is-/ai- n21477915?tag=artBody;col1